Læknaneminn - 01.04.1997, Side 134

Peter Duesberg and David Rasnick
128. Clair DA. Drug treatment specialist of the Federal Bureau of
Prisons, Greenville IL. personal communication August 1996;
129. Weil A, Rosen W. Chocolate and morphine. Houghton Mifflin
Co., Boston, 1983.
130. Haverkos HW, Dougherty JA (eds.) Health Hazards of Nitrite
Inhalants (1988), US. Dept. Health &c Human Services,
Washington, DC, .
131. Dax EM, Nagel JE, Lange WR, Adler WH, Jaffe JH. Effects of
nitrites on the immune system of humans, in Health hazards of
nitrite inhalants, H. W. Haverkos and J. A. Dougherty (eds.) Dept.
Health &c Human Services, Washington, DC, 1988; 75-79.
132. Goedert JJ, Neuland CY, Wallen WC, Greene MH, Mann DL,
Murray C, Strong DM, Fraumeni JF, Jr., Blattner WA. Amyl nitrite
may alter T lymphocytes in homosexual men. Lancet 1982; i: 412-
416.
133. Nieman RB, Fleming J, Coker RJ, Harris JR, Mitchell DM. The
effect of cigarette smoking on the development of AIDS in HIV-1-
seropositive individuals. AIDS 1993; 7: 705-710.
134. Lewis RJS. Food additives handbook. Van Nostrand Reinhold,
New York, NY 10003, 1989.
135. Winter R. A consumer’s dictionary of food additives. Crown
Publishers, Inc., New York, NY 10022, 1989.
136. Mirvish SS, Williamson J, Babcook D, Sheng-Chong C.
Mutagenicity of iso-butyl nitrite vapor in the Ames test and some
relevant chemical properties, including the reaction of iso-butyl
nitrite with phosphate. Environmental and Molecular Mutagenesis
1993; 21: 247-252.
137. National Research Council. Diet, nutrition, and cancer. National
Acad. Press, Washington, D.C., 1982.
138. Newell GR, Mansell PWA, Spitz MR, Reuben JM, Hersh EM.
Volatile nitrites: Use and adverse effects related to the current epi-
demic of the acquired immune deficiency syndrome. Am J Med
1985; 78: 811-816.
139. Cox GD. County health panel urges ‘poppers’ ban, cites AIDS link.
The Los Angeles Daily Journal (Los Angeles) 1986: Section II, p.l,
Mar. 24.
140. Haverkos HW. Nitrite inhalant abuse and AIDS-related Kaposi’s
sarcoma. JAIDS 1990; 3: Supplement 1, S47-S50.
141. Ratajczak HV, Thomas PT, House RV, Gaworski CL, Sherwood RL,
Luster MI, Hagen KL, Abdo K, Jackson CD, Roycroft J, Aranyi C.
Local versus Systemic Immunotoxicity of Isobutyl Nitrite Following
Subchronic Inhalation Exposure of Female B6C3F1 Mice.
Fundamental and Applied Toxicology 1995; 27: 177-184.
142. Pink Paper. Shops on their guard after poppers sale legal setback.
The Pink Paper (London) 1996: June 28.
143. Seligmann M, Chess L, Fahey JL, Fauci AS, Lachmann PJ, L’Age-
Stehr J, Ngu J, Pinching AJ, Rosen FS, SpiraTJ, Wybran J. AIDS—
an immunologic reevaluation. N Engl J Med 1984; 311: 1286-
1292.
144. Lauritsen J, Wilson H. Death Rush, Poppers and AIDS. Pagan
Press, New York, 1986.
145. Moss AR. AIDS and intravenous drug use: the real heterosexual epi-
demic. Br Med J 1987; 294: 389-390.
146. Kolata G. New picture of who will get AIDS is dominated by
addicts. New YorkTimes (New York) 1995: Sect. C, p3, February
28.
147. Furman PA, Fyfe JA, St Clair M, Weinhold K, Rideout JL, Freeman
GA, Nusinoff-Lehrman S, Bolognesi DP, Broder S, Mitsuya H,
Barry DW. Phosphorylation of 3’-azido-3’-deoxythymidine and
selective interaction of the 5’-triphosphate with human immunode-
ficiency virus reverse transcriptase. PNAS 1986; 83: 8333-8337.
148. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding
PA, Laskin OL, Leedon JM, Groopman JE, Mildvan D, Schooley
RT, Jackson GG, Durack DT, King D, the AZT Collaborative
Working Group. The efficacy of azidothymidine (AZT) in the treat-
ment of patients with AIDS and AIDS-related complex. N Engl J
Med 1987; 317: 185-191.
149. Kolata G. Imminent marketing of AZT raises problems; Marrow
suppression hampers AZT use in AIDS victims. Science 1987; 235:
1462-1463.
150. Kramer L. A good news/bad new AIDS joke. New York Times
(New York) 1996: 26, Sunday, July 14.
151. Nussbaum B. Good Intentions: How Big Business, Politics, and
Medicine are Corrupting the Fight Against AIDS. Atlantic Monthly
Press, New York, 1990.
152. Physicians’ Desk Reference. Retrovir. Medical Economics Co.,
Orandell, NJ, 1994.
153. Mansuri MM, Hitchcock MJM, Buroker RA, Bregman CL,
Ghazzouli I, Desiderio JV, Starrett JE, Sterzycki RZ, Martin JC.
Comparison of in vitro biological properties and mouse toxicities of
three thymidine analogs active against human immunodeficiency
virus. Antimicrobial Agents and Chemotherapy 1990; 34: 637-641.
154. Lemaítre M, Guetard D, Henin Y, Montagnier L, Zerial A.
Protective activity of tetracycline analogs against the cytopathic
effect of the human immunodeficiency viruses in CEM cells. Res
Virol 1990; 141: 5-16.
155. Avramis VI, Markson W, Jackson RL, Gomperts E. Biochemical
pharmacology of zidovudine in human T-lymphoblastoid cells
(CEM). AIDS 1989; 3: 417-422.
156. Sommadossi J-P, Zhu Z, Carlisie R, Xie M-Y, Weidner DA, E1
Kouni MH. Novel pharmacological approaches to the treatment of
AIDS and potential use of uridine phosphorylase inhibitors, in
Advances in Chemotherapy of AIDS, R. B. Diasio and J.-P.
Sommadossi (eds.) Pergamon Press Inc., New York, 1990; 63-73.
157. Inoue T, Tsushita K, Itoh T, Ogura M, Hotta T, Saneyoshi M,
Yoshida S, Saitoh H, Tomoda Y, Nagai Y. In vitro bone marrow tox-
icity of nucleoside analog against human immunodeficiency virus.
Antimicrob Agents Chemother 1989; 33: 576-579.
158. Gogu SR, Beckman BS, Agrawal KC. Anti-HIV drugs:
Comparative toxicities in murine fetal liver and bone marrow ery-
throid progenitor cells. Life Sci 1989; 45: iii-vii.
159. Chiu D, Duesberg P. The Toxicity of Azidothymidine (AZT) on
Human and Animal Cells in Culture at Concentrations Used for
Antiviral Therapy. Genetica 1995; 95: 103-109.
160. Seligmann M, Warrell DA, Aboulker J-P, Carbon C, Darbyshire JH,
Dormont J, Eschwege E, Girling DJ, James DR, Levy J-P, Peto PTA,
Schwarz D, Stone AB, Weller IVD, Withnall R, Gelmon K, Lafon
E, Swart AM, Aber VR, Babiker AG, Lhoro S, Nunn AJ, Vray M.
Concorde: MRC/ANRS randomised double-blind controlled trial of
immediate and deferred zidovudine in symptom-free HIV infection.
Lancet 1994; 343: 871-881.
161. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW,
Booth DK, Balfour HH, Jr., Reichman RC, Bartlett JA, Hirsch MS,
Murphy RL, Hardy WD, Soeiro R, Fischl MA, Bartlett JG, Merigan
TC, Hyslop NE, Richman DD, Valentine FT, Corey L, the AIDS
Clinical Trial Group of the National Insitute of Allergy and
Infectious Disease. Zidovudine in asymptomatic human immunod-
eficiency virus infection: A controlled trial in persons with fewer
than 500 CD4-positive cells per cubic millimeter. N Engl J Med
1990; 322: 941-949.
162. Mir N, Costello C. Zidovudine and bone marrow. Lancet 1988; ii:
1195-1196.
163. Dournon E, Matheron S, Rozenbaum W, Gharakhanian S, Michon
C, Girard PM, Perrone C, Salmon D, DeTruchis P, Leport C, the
Claude Bernard Hospital AZT Study Group. Effects of zidovudine
in 365 consecutive patients with AIDS or AIDS-related complex.
Lancet 1988; ii: 1297-1302.
164. van Leeuwen R, van den Hurk PJ, Jöbis GJ, van der Wouw PA, Reiss
P, Eeftinck Schattenkerk JKM, Danner SA, Lange JMA. Failure to
maintain high-dose treatment regimens during long-term use of
zidovudine in patients with symptomatic human immunodeficiency
virus type 1 infection. Genitourin Med 1990; 66: 418-422.
165. Swanson CE, Cooper DA, the Australian Zidovudine Study Group.
Factors influencing outcome of treatment with zidovudine of
patients with AIDS in Australia. AIDS 1990; 4: 749-757.
166. Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond
GR, Dickinson GM, Drusano GL, Egorin MJ, George WL, Gordin
FM, the Veterans Affairs Cooperative Study Group on AIDS
Treatment. A controlled trial of early versus late treatment with
zidovudine in symptomatic human immunodeficiency virus infec-
tion. N Engl J Med 1992; 326: 437-443.
167. Horwitz JP, Chua J, Noel M. Nucleosides.V. The monomesylates of
l-(2’-deoxy-beta-D-lyxofuranosyl)thymidine. J Org Chem 1964;
•29: 2076.
LÆKNANEMINN
132 1. tbl. 1997, 50. árg.